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suggested by the comparison between real and simulated 
images. 
These results question the use of PET imaging as a target for 
dose painting by numbers in lung cancer. 
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Purpose or Objective: To determine the patterns of 
locoregional failure (LRF) in patients with locally advanced 
non-small cell lung cancer treated with definitive 
radiotherapy (RT). 
 
Material and Methods: One hundred and fifty-four patients 
from the Gating 2006 prospective randomized trial 
(NCT00349102) were treated with conformal RT with or 
without respiratory motion management. All patients had a 
PET-CT with 18FDG in the two months leading up to study 
inclusion. The recommended protocol prescription was 66 Gy 
in daily 2-Gy fractions, five days a week. IMRT was not 
permitted. Patients with a LRF as first event were included. 
Treatment plannings with simulation CT, pre-treatment 
18FDG PET-CT and post-treatment images demonstrating 
recurrence were registered and analyzed. Measurable LRF 
was contoured (rGTV) and classified as in-field (if 95% of 
rGTV volume was within the 95% isodose), marginal (if 20 to 
95% of rGTV volume was within the 95% isodose), or out-of-
field (if less than 20% of rGTV volume was within the 95% 
isodose). 
 
Results: Median follow-up was 27.8 months. Forty-eight 
patients presented LRF. One-year and 2-year locoregional 
disease-free survival were 77% (95% CI 70-83) and 72% (95% CI 
64-79) respectively. Age was the only independent LRF 
prognostic factor. The median age for patients in LRF was 67 
years vs 60 years for the group not in LRF (p=0.009). 79% of 
the patients with LRF as first event relapsed within the RT 
field. 32% of patients with LRF had a marginal LRF 
component. Isolated out-of-field failure occurred in only 3% 
of all patients. The regions of highest FDG-uptake on pre-
treatment PET-CT were located within the recurrence in 91% 
of patients with in-field LRF. 
 
Conclusion: In-field failure was the most common pattern of 
failure. Escalated dose RT with high-dose fractions guided by 
PET parameters warrants further investigation. 
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Purpose or Objective: Treatment of lung cancer (LC) with 
radiotherapy (RT) is often accompanied by the development 
of relapse. The significance of biologic markers for predicting 
recurrence has been increasingly emphasized by recent 
studies. Highly accurate and reliable machine-learning 
approaches can drive the success of biomarkers identification 
in clinical care. We developed a prospective platform to 
incorporate translational research into the clinical decision 
making process in LC patients. 
 
Material and Methods: Prospective data from 138 
consecutive LC patients with indication of 
radio(chemo)therapy and diagnosis from January 2013 to 
August 2014 were available to enable the development of a 
prediction model. Median age was 62.5 years-old (range, 35-
88) and the Karnofsky performance status (KPS) was ≥70 
except for 129 cases. The most common histology for non-
small cell LC patients (77.5%) was squamous cell carcinoma 
(52.3%). 73.1 percent of patients had Stage III disease (9 
cases were a mediastinum recurrence) and 91 % received 
platinum-based chemotherapy. Median total dose prescribed 
was 61.2 Gy. 20 cases also underwent surgery. Data from 
translational research included genotypes of 4 single 
nucleotide polymorphisms (SNPs) of the transforming growth 
factor (TGFB1) gene (rs4803455, rs1800468, rs8179181, and 
rs8110090) and 3 SNPs of the heat shock protein (HSPB1) gene 
(rs2868370, rs2868371, and rs7459185). 
 
Results: In univariate analysis, the CA genotype (N=92; 64 
relapses [70%]) of TGFB1 rs4803455 was associated with a 
statistically significantly higher risk of recurrence (OR = 2.09; 
P = 0.045) compared with the CC genotype (N=46; 24 relapses 
[52%]). This effect was virtually unchanged after multivariate 
analysis (OR = 2.31; 95% CI, 1.08– 4.95; P = 0.031). In 
addition, we performed an ROC curve analysis to determine 
the strength of the above identified biomarker in predicting 
relapse. Age was the most important predictor, with an AUC 
of 0.62. By adding the TGFB1 rs4803455 SNP, the predictive 
power of the recurrence risk model improved, enhancing the 
AUC to 0.67 (95% CI, 0.57– 0.76; P = 0.001). 
 
Conclusion: The prediction model for recurrence of patients 
with LC highlights the importance of combining patient, 
clinical, treatment, and translational variables. Our results 
showed that the CA genotype of TGFB1 rs4803455 SNP was 
associated with a higher risk of relapse in patients with LC 
treated with radio(chemo)therapy and thus may be used for 
guiding therapy intensity or as a selection criteria for a 
clinical trial, which would further the goal of individualized 
therapy. This tool could be used as a first building block for a 
decision support system. 
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Purpose or Objective: To evaluate loco-regional patterns of 
failure after induction chemotherapy and surgical resection 
for stage III N2 non–small-cell lung cancer (NSCLC). 
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Material and Methods: This retrospective study included 151 
patients with pathological confirmed diagnosis of stage III-N2 
NSCLC from 1998 to 2012, at the University Hospitals Leuven 
and the Oncologic Center Limburg. All patients were treated 
with induction chemotherapy and surgical resection. 
Postoperative radiotherapy (PORT) was only performed in 
case of incomplete resection (R1/R2) or persistent nodal 
disease (ypN2). For the non-PORT group, we created a virtual 
PTV, consisting of the initially involved lymph node stations, 
N7, the ipsilateral hilum and bronchial stump. All patients 
were staged with FDG PET-CT and brain imaging. Disease 
recurrence at the primary affected lobe of the lung, 
ipsilateral hilum, and/or initially involved mediastinal nodes 
was considered loco-regional (LR). R2 resections were also 
seen as LR. Follow-up occurred at 3-month intervals for the 
ﬁrst 2 years, every 6 months for the next 3 years, and then 
annually and included physical examination, blood test and 
CT scan of thorax and upper abdomen each 6 months. 
 
 
 
Results: After a mean follow-up of 46 months, disease 
recurrence occurred in 96/151 patients. Cumulative LR and 
distant metastases (DM) were seen in 39% (59/151) and 57% 
(86/151), respectively. Forty-eight patients (32%) had a LR as 
first event. PORT was performed in 76 patients. Considering 
the patients with cumulative LR (n=59), patients who 
underwent PORT (n=27) had a total of 60 relapse sites (2.2 
sites/patient), whereas in the non-PORT group (n=32) a total 
of 98 sites were documented (3.1 sites/patient)(p<0.05). 
In the PORT-group, the most common site of failure was the 
hilum, followed by station 7, the bronchial stump, 4R, 2R, 5-
6, 4L, 2L, 3 and 8-9. In the non-PORT group, the most 
common site of failure was station 7, followed by station 4R, 
the hilum, 2R, 4L, 5-6, the bronchial stump, 8-9 and 2L 
(table).  
In the PORT group, 33% of patients relapsed inside the 
planning target volume (PTV), 33% had a local relapse both 
within and outside the PTV. Another 18% of patients had a LR 
outside the PTV. In the non-PORT group, 66% of patients 
relapsed inside the virtual PTV, 31% both within and outside 
the PTV, and only 3% had a LR outside the PTV. 
 
Conclusion: Patients receiving PORT had less sites of LR 
compared to the non-PORT group. In the non-PORT group, 
significantly more relapses were seen in nodal station 7, 4R 
and 4L, which are in the majority of cases irradiated in the 
PORT group. These data indicate the potential benefit of 
PORT in stage III N2 NSCLCL treated with induction 
chemotherapy and surgery. 
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Purpose or Objective: Malignant pleural mesothelioma 
(MPM) has an aggressive course, high mortality rate and no 
standard of care. The role of radiotherapy has not been 
established. In a dose escalation study of moderate 
hypofractionated tomotherapy(HTT) we obtained statistically 
significant better local control adding a simultaneous 
integrated boost (SIB) on FDG-PET positive areas (BTV) (Fodor 
et al, Strahlenter Onkol 2011). Here we evaluate factors 
influencing outcome in MPM patients(pts) treated with HTT. 
 
Material and Methods: From May 2006 to April 2014 54 pts 
with MPM, progressive after previous treatments (surgery + 
chemotherapy) were treated with salvage HTT. Patient 
characteristics are presented in the table below. Median 
survival was 10.2 (1.18-70) months, 4 patients, all treated 
with SIB, were alive at the last follow up. A univariate 
analysis was performed to identify which of these factors: 
BTV boost, volume of BTV, type of surgery, histology, stage, 
chemotherapy yes/no and volume of PTV influence Overall 
Survival(OS), Local Relapse(LR) and Distant and Local 
Relapse(R). 
 
 
 
Results: Median survival for initial stage I vs II vs III vs IV was: 
10.2: 22.07:9.97:5.72 (p=0.006). Only stage (I-II vs III-IV) was 
statistically significant in predicting OS: 13.11 vs 8.23 
months(mts) (p=0.04) and only surgery yes(EPP/P) vs 
Biopsy/Talc Pleurodhesis (TP) for LR(p=0.009). SIB on BTV has 
an impact on survival for stage III-IV (p=0.05), but not for 
stage I-II (p=0.7). A BTV volume of 353.2 cc was found to be 
the best cut-off having a statistically significant impact on OS 
(p= 0.0003). Median OS was 5.84 vs 7.8 vs 11.54 (p=0.04) for 
pts without SIB vs pts with SIB and BTV volume > cut off vs 
pts with BTV < cut-off. BTV volume< 353.2 cc significantly 
influences OS in stage III-IV (p=0.03). In stage III-IV SIB has a 
role in BTV< 353.2 cc, and pts with higher BTV treated with 
SIB have similar OS to pts without boost: 11.54 vs 6 vs 4.85 
mts (p=0.04). In stages III-IV, type of surgery was significant 
for OS: EPP vs P vs TP= 1.61: 10.1:8.23 (p=0.001). For pts 
with TP BTV volume <353.2 cc is a significant predictor of 
survival (p=0.001) and these pts have a better OS than pts 
with larger BTV treated with SIB or without SIB: 13.11 vs 7.8 
vs 7.74(p=0.04). 
 
 
Conclusion: The BTV cut off volume <353.2 cc significantly 
influences OS in stage III-IV pts , even in those treated with 
palliative surgery, but irradiated with SIB and can help in 
patient selection for salvage SIB HTT. 
